Literature DB >> 16807154

Irritable bowel syndrome: the burden and unmet needs in Europe.

E M M Quigley1, P Bytzer, R Jones, F Mearin.   

Abstract

Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. This may be due to differences in patterns of medical care and diagnosis of the condition. Up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed. The disorder affects 1.5-3 times as many women as men and poses a significant economic burden in Europe, estimated at euro 700-euro 1600 per person per year. It also reduces quality of life and is associated with psychological distress, disturbed work and sleep, and sexual dysfunction. It is a chronic disorder, which affects many individuals for more than 10 years. Most patients are managed in primary care, although some are referred to gastroenterologists and other specialists. Patients with irritable bowel syndrome undergo more abdomino-pelvic surgery than the general population. We propose that a positive diagnosis of the condition may avoid the delay in diagnosis many patients experience. We conclude that, in Europe, there are significant unmet needs including lack of familiarity with irritable bowel syndrome, difficulties in diagnosis and lack of effective treatments for the multiple symptoms of the disorder. The development of pan-European guidelines for irritable bowel syndrome will benefit patients with this condition in Europe.

Entities:  

Mesh:

Year:  2006        PMID: 16807154     DOI: 10.1016/j.dld.2006.05.009

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  23 in total

Review 1.  Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders?

Authors:  S Heuston; N P Hyland
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Current and emerging therapies for the management of functional gastrointestinal disorders.

Authors:  Orla F Craig; Eamonn M M Quigley
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

3.  The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.

Authors:  Octavian Alexea; Vlad Bacarea; Núria Piqué
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

Review 4.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

5.  Sexual activity does not predispose to reflux episodes in patients with gastroesophageal reflux disease.

Authors:  Serhat Bor; Elen Valytova; Suna Yapali; Esra Yildirim; Rukiye Vardar
Journal:  United European Gastroenterol J       Date:  2014-12       Impact factor: 4.623

6.  Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome.

Authors:  Anne Line Engsbro; C Rune Stensvold; Henrik V Nielsen; Peter Bytzer
Journal:  Am J Trop Med Hyg       Date:  2012-10-22       Impact factor: 2.345

7.  Irritable bowel syndrome: physicians' awareness and patients' experience.

Authors:  Linda Bjork Olafsdottir; Hallgrímur Gudjonsson; Heidur Hrund Jonsdottir; Jon Steinar Jonsson; Einar Bjornsson; Bjarni Thjodleifsson
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 8.  Visceral pain: the ins and outs, the ups and downs.

Authors:  Shafaq Sikandar; Anthony H Dickenson
Journal:  Curr Opin Support Palliat Care       Date:  2012-03       Impact factor: 2.302

9.  An investigation of fecal volatile organic metabolites in irritable bowel syndrome.

Authors:  Iftikhar Ahmed; Rosemary Greenwood; Ben de Lacy Costello; Norman M Ratcliffe; Chris S Probert
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

10.  Irritable bowel syndrome.

Authors:  Per G Farup; Ami D Sperber; Magnus Simrén
Journal:  Gastroenterol Res Pract       Date:  2012-05-07       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.